PragmaTIL Pragmatic approach to Adoptive Cell Therapy (ACT) using Tumor Infiltrating Lymphocytes (TIL) in selected solid tumors
- Coordinator
- Fundacio Privada Institut D'investigacio Oncologica De Vall-Hebron (vhio), Spain
- Runs
- 1 April 2023 to 31 March 2028
- Status
- Running
- EU funding
- €6.0m
- Total cost
- €6.0m
- Partners
- 13 organisations in 6 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101104684
What the project is doing
In the project's own words, from its summary on CORDIS.
The PragmaTIL trial aims to optimize treatment of cancer patients with Tumour-Infiltrating Lymphocytes Adoptive Cell Therapy (TIL-ACT) and substantially expand and improve the clinical implementation of this treatment modality in academic hospitals. To this end, treatment related toxicities, associated to high-dose interleukin 2 (HD-IL-2) required for expansion and activation of TILs will be reduced while maintaining efficacy.
This improved tolerability will achieve a better clinical management of patients and enhance their quality of life, both of which represent major barriers for applying this treatment. The objectives of PragmaTIL are: i) To determine whether TIL-ACT using IL-2 analog ANV600 reduces the frequency of Grade ≥3 study-related non-hematological toxicities
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Fundacio Privada Institut D'investigacio Oncologica De Vall-Hebron (vhio) | Barcelona | Spain | Coordinator |
| Region Hovedstaden | Hillerod | Denmark | Participant |
| Asphalion SL | Barcelona | Spain | Participant |
| Banc De Sang I Teixits | Barcelona | Spain | Third party |
| Bcn Health Economics & Outcomes Research SL | Barcelona | Spain | Participant |
| Fundacion Bancaria Caixa D Estalvis I Pensions De Barcelona La Caixa | Barcelona | Spain | Participant |
| Innovandum Health SL | Valencia | Spain | Participant |
| Citoyens Et Recherche | Paris | France | Participant |
| Institut Gustave Roussy | Villejuif | France | Participant |
| Unicancer | Paris | France | Participant |
| Medical Research Infrastructure Development and Health Services Fund by the Sheba Medical Center | Ramat Gan | Israel | Participant |
| Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek Ziekenhuis | Amsterdam | Netherlands | Participant |
| Region Stockholm | Stockholm | Sweden | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI